September 19, 2012
Dainippon Sumitomo Pharma (DSP) announced on September 18 that Sunovion Pharmaceuticals Canada, a subsidiary of DSP’s US subsidiary Sunovion, launched the atypical antipsychotic drug Latuda (lurasidone) in Canada on September 17. DSP obtained approval for the drug in June this...read more